[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354230-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354230-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","site-specific-genomic-markers-associated-with-outcomes-of-pd-1-blockade-in-gastric-and-esophagogastric-junction-cancer-analysis-of-japans-c-cat-registry","Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer - Analysis of Japan’s C-CAT Registry","","Background advanced gastric cancer (GC) and esophagogastric junction (EGJ) adenocarcinoma show limited durable response to anti–programmed cell death 1 (PD-1) therapy, leaving a need for actionable biomarkers. Objective identify tumor site-specific genomic alterations linked to outcomes of nivolumab monotherapy in a nationwide real-world cohort. Methods retrospective analysis using Japan’s C-CAT registry (July 2019–April 2024), evaluating time to treatment failure and overall survival with exploratory gene-level associations after adjustment for age and sex.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/site-specific-genomic-markers-associated-with-outcomes-of-pd-1-blockade-in-gastric-and-esophagogastric-junction-cancer-analysis-of-japans-c-cat-registry/354230/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/site-specific-genomic-markers-associated-with-outcomes-of-pd-1-blockade-in-gastric-and-esophagogastric-junction-cancer-analysis-of-japans-c-cat-registry/354230.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are biomarkers needed for PD-1 therapy in advanced gastric and EGJ cancer?","Question",{"text":63,"@type":64},"Only a minority of patients derive durable benefit from anti–PD-1 therapy, and reliable biomarkers for real-world decision-making remain limited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study cohort and analysis designed?",{"text":68,"@type":64},"A retrospective nationwide analysis used Japan’s C-CAT registry, including GC and EGJ adenocarcinoma patients treated with nivolumab monotherapy from July 2019 to April 2024. Outcomes included time to treatment failure and overall survival, with multivariable models adjusted for age and sex.",{"name":70,"@type":61,"acceptedAnswer":71},"What genomic associations differed by tumor site?",{"text":72,"@type":64},"In GC, ASXL1 mutation was associated with longer time to treatment failure, and MSI-H plus FANCG were associated with longer overall survival while CDH1 was associated with shorter overall survival. In EGJ cancer, NTRK1 related to longer time to treatment failure, while MUTYH related to shorter overall survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354230,1790470180,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","BioDrugs (2026) 40:497–516  \n[https://doi.org/10.1007/s40259-026-00779-9](https://doi.org/10.1007/s40259-026-00779-9)  \nSite‑Specific Genomic Markers Associated with Outcomes of PD‑1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C‑CAT Registry  \nYasuyoshi Sato1,2 · Koichi Yagi2 · Kazunaga Ishigaki1,3 · Raito Asaoka2 · Kotaro Sugawara2 · Shuichiro Oya2 · Asami Okamoto2 · Yoshiyuki Miwa2 · Shoh Yajima2 · Yoshifumi Baba2 · Kousuke Watanabe4 · Katsutoshi Oda4 · Mitsuhiro Fujishiro1,3  \nAccepted: 5 April 2026 / Published online: 27 April 2026 © The Author(s) 2026  \nAbstract  \nBackground Only a minority of patients with advanced gastric cancer (GC) or esophagogastric junction (EGJ) adenocarcinoma derive durable benefit from anti-programmed cell death 1 (PD-1) therapy. However, reliable biomarkers for real-world clinical decision-making remain limited.  \nObjective To identify tumor site-specific genomic alterations associated with outcomes of nivolumab monotherapy in a nationwide real-world cohort.  \nMethods We conducted a retrospective nationwide analysis using Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT) registry, including patients with GC and EGJ cancer adenocarcinoma treated with nivolumab monotherapy (July 2019–April 2024). Primary endpoints were time to treatment failure (TTF) and overall survival (OS), defined as the interval from nivolumab initiation to death from any cause; objective response rate (ORR) was secondary. Gene-level alteration indicators were derived from vendor-reported tumor-only panel calls across multiple platforms and filtered for clonal hematopoiesis of indeterminate potential (CHIP)-like variants (variant allele frequency \u003C 0.05) . Multivariable models adjusted for age and sex were fitted separately for GC and EGJ cancer. Variant pathogenicity was based on available panel annotations; therefore, gene-level results should be interpreted as exploratory findings.  \nResults Among 798 patients with GC and 114 patients with EGJ cancer adenocarcinoma, median TTF/OS/ORR were 3.98 months/20 .2 months/11 .7% in GC and 4.80 months/24 .7 months/14 .9% in EGJ cancer adenocarcinoma. In GC, ASXL1 mutation remained independently associated with longer TTF (hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.37–0.94) after adjustment and CHIP filtering. For OS, microsatellite instability-high [MSI-H](HR 0.16, 95% CI 0.04–0.70) and FANCG (HR 0.37, 95% CI 0.16–0.87) were associated with longer OS, whereas CDH1 (HR 1.51, 95% CI 1.10–2.05) was associated with shorter OS. In EGJ cancer adenocarcinoma, NTRK1 mutation correlated with longer TTF (HR 0.31, 95% CI 0.10–0.98) and MUTYH with shorter OS (HR 5.68, 95% CI 2.04–15.81), both exploratory.  \nConclusions In this large Japanese real-world cohort, genomic associations with nivolumab outcomes differed by tumor site. In gastric cancer, ASXL1 mutation was associated with prolonged treatment benefit under PD-1 blockade, while CDH1 and FANCG showed exploratory associations with OS. These findings warrant further validation in prospective and platform-controlled analyses.  \n* Yasuyoshi Sato [yasuyoshi_s@hotmail.com](yasuyoshi_s@hotmail.com)  \n1 Department of Clinical Oncology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  \n2 Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  \n3 Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  \n4 Department of Clinical Genomics, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  \n1 Introduction  \nTogether, gastric cancer (GC) and esophagogastric junction (EGJ) adenocarcinoma remain the 5th major cause of cancer mortality worldwide. There is a disproportionate burden in East Asia [1], where diffuse-type histology is more common and outcomes after standard cyt","cbCaiqjFoQK4MLpP","https://ap.wps.com/l/cbCaiqjFoQK4MLpP","pdf",1618721,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Clinical burden and treatment context\n## Rationale for biomarker search\n## Limitations of existing biomarkers","[{\"question\":\"Why are biomarkers needed for PD-1 therapy in advanced gastric and EGJ cancer?\",\"answer\":\"Only a minority of patients derive durable benefit from anti–PD-1 therapy, and reliable biomarkers for real-world decision-making remain limited.\"},{\"question\":\"How was the study cohort and analysis designed?\",\"answer\":\"A retrospective nationwide analysis used Japan’s C-CAT registry, including GC and EGJ adenocarcinoma patients treated with nivolumab monotherapy from July 2019 to April 2024. Outcomes included time to treatment failure and overall survival, with multivariable models adjusted for age and sex.\"},{\"question\":\"What genomic associations differed by tumor site?\",\"answer\":\"In GC, ASXL1 mutation was associated with longer time to treatment failure, and MSI-H plus FANCG were associated with longer overall survival while CDH1 was associated with shorter overall survival. In EGJ cancer, NTRK1 related to longer time to treatment failure, while MUTYH related to shorter overall survival.\"}]","Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer - Analysis of Japan’s C-CAT Registry | PDF",1790109662,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90e6e1920ba945c1ca4d8585a2a4d107.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d8650106e4404ceb6acba6d50da9528.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfc4c954b7df7814f89b15f76937bdd3.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fceb19686b1410031470580b882a68df.webp",980,1301]